XCancer
Perspective Therapeutics

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Description:

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Sponsor:

Perspective Therapeutics

Phase:

Phase 1/2

Contacts:

ClinicalTrials at Perspectivetherapeutics (CONTACT)

clinicaltrials@perspectivetherapeutics.com

(206) 676-0900

Government Study Link:

NCT06710756 - Click here to see study on

ClinicalTrials.gov

PSV359

Isotope(s):
Target(s):
  • FAP
Ligand Class: Peptides

PSV359

Isotope(s):
Target(s):
  • FAP
Ligand Class: Peptides
Inclusion
  • Progressive disease despite standard therapy or for whom no standard therapy exists
  • * Aged ≥ 18 years
  • Satisfactory organ function as determined by laboratory testing
  • Eastern Cooperative Oncology Group performance (ECOG) status of 0 to 1
  • Life expectancy \> 3 months
Exclusion
  • Pregnancy or breastfeeding a child
  • Known brain metastases
  • Active secondary malignancy
  • * Known hypersensitivity to the active agent or any of the excipients
  • Known active or uncontrolled infections requiring ongoing antifungals or antibiotics in the 3 days prior to enrollment

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Loading...